Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata, but identified as OncoGenex in the filing text) for the reporting period of December 3, 2008. The company is a Delaware corporation headquartered in Bothell, Washington, operating in the pharmaceutical sector.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure rather than a financial statement.
Material Changes
The primary material event reported is a clinical trial update regarding the company's drug candidate, OGX-011. On December 3, 2008, the company announced that OGX-011 demonstrated an overall survival advantage compared to standard therapy in a randomized Phase 2 study for prostate cancer.
Guidance, Outlook, and Risks
- Management Commentary: The filing incorporates a press release (Exhibit 99.1) detailing the positive Phase 2 study results for OGX-011.
- Regulatory Status: The information in this report, including the attached press release, is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Risks and Contingencies: No specific risks or contingencies are detailed in the body of this 8-K, though clinical trial results inherently carry regulatory and commercialization risks.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical data on the OGX-011 survival advantage.
- Confirm the company's current name and ticker status, as the metadata lists "ACHIEVE LIFE SCIENCES, INC." while the filing identifies "ONCOGENEX PHARMACEUTICALS, INC."
- Review subsequent filings to determine if the Phase 2 results led to regulatory approval or further clinical development.
- Check the company's most recent 10-K or 10-Q for actual financial metrics, as this 8-K contains no financial data.